Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor antigen-sensitized DC vaccine in esophageal cancer
NCT05023928Phase 1Completed
- Sponsor
- Sichuan University
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tumor antigen-sensitized dendritic cell vaccine in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan University. Primary endpoint: Number of participants with treatment-related adverse events at 3 months. Started Sep 2021; status: completed.
02
Drugs
tumor antigen-sensitized dendritic cell vaccine
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05023928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023928.